Allogene Therapeutics Inc (ALLO)vsNovartis AG ADR (NVS)

ALLO

Allogene Therapeutics Inc

NASDAQ

$2.13

+0.95%

HEALTHCARE · Cap: $725.79M

NVS

Novartis AG ADR

NYSE

$147.85

+3.44%

HEALTHCARE · Cap: $282.11B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

ALLO

Avoid

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 5.0

NVS

Buy

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5

Piotroski: 4/9Altman Z: 1.96

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ALLO.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALLO1 strengths · Avg: 8.0/10

Price/BookValuation

1.7x8/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

ALLO4 concerns · Avg: 3.3/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$725.79M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Operating MarginProfitability

0.0%3/10

Operating margin of 0.0%

NVS4 concerns · Avg: 3.0/10

PEG RatioValuation

2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth

-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALLO

The strongest argument for ALLO centers on Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : ALLO

The primary concerns for ALLO are EPS Growth, Market Cap, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

ALLO profiles as a value stock while NVS is a declining play — different risk/reward profiles.

ALLO carries more volatility with a beta of 0.54 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 23/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Allogene Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

ALLO vs VRTX ALLO vs REGN ALLO vs ARGX ALLO vs ALNY ALLO vs ONC NVS vs VRTX NVS vs REGN NVS vs ARGX NVS vs ALNY NVS vs ONC

Want to dig deeper into these stocks?

Full ALLO Analysis →Full NVS Analysis →